Fortrea Holdings (FTRE) Cost of Revenue (2022 - 2026)
Fortrea Holdings (FTRE) reported Cost of Revenue of $512.9 million for Q1 2026, down 4.09% on a YoY basis from $534.8 million in Q1 2025, and down 3.12% quarter-over-quarter from $529.4 million in Q4 2025.
Fortrea Holdings (FTRE) Cost of Revenue (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Cost of Revenue for 5 years, with the latest figure at $512.9 million in Q1 2026.
- For the quarter ending Q1 2026, Cost of Revenue fell 4.09% year-over-year to $512.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 billion (up 2.56% YoY), and the FY2025 full-year result was $2.2 billion, up 2.65% from the prior year.
- Cost of Revenue for Q1 2026 stood at $512.9 million, down from $529.4 million in the prior quarter.
- The five-year high for Cost of Revenue was $614.3 million in Q2 2022, with the low at $265.0 million in Q4 2022.
- Historically, Cost of Revenue has averaged $538.8 million across 5 years, with a median of $555.2 million in 2024.
- Annual changes were most pronounced in 2023 — Cost of Revenue jumped 118.08% — and 2024, when it decreased 7.63%.
- Fortrea Holdings' Cost of Revenue stood at $265.0 million in 2022, then jumped by 118.08% to $577.9 million in 2023, then declined by 3.77% to $556.1 million in 2024, then fell by 4.8% to $529.4 million in 2025, then declined by 3.12% to $512.9 million in 2026.
- The last three Cost of Revenue figures came in at $512.9 million (Q1 2026), $529.4 million (Q4 2025), and $578.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 64.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 48,670.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 392.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 2.05 Mn |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | 512.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 512.90 Mn |
| Mar 31, 2026 | 512.90 Mn |
| Dec 31, 2025 | 529.40 Mn |
| Dec 31, 2025 | 529.40 Mn |
| Sep 30, 2025 | 578.60 Mn |
| Sep 30, 2025 | 578.60 Mn |
| Jun 30, 2025 | 576.80 Mn |
| Jun 30, 2025 | 576.80 Mn |
| Mar 31, 2025 | 534.80 Mn |
| Mar 31, 2025 | 534.80 Mn |
| Dec 31, 2024 | 556.10 Mn |
| Dec 31, 2024 | 556.10 Mn |
| Sep 30, 2024 | 526.60 Mn |
| Sep 30, 2024 | 526.60 Mn |
| Jun 30, 2024 | 525.30 Mn |
| Jun 30, 2024 | 525.30 Mn |
| Mar 31, 2024 | 554.20 Mn |
| Mar 31, 2024 | 554.20 Mn |
| Dec 31, 2023 | 577.90 Mn |
| Dec 31, 2023 | 577.90 Mn |